Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

798
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
798
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

3.1K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.1K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

737
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
737
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

280
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
280
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

830
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
830
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

232
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
232

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unraveling the Complex Genomic Interplay of Sickle Cell Disease Among the Saudi Population: A Case-Control GWAS Analysis.

International journal of molecular sciences·2025
Same author

Blueprint for Constructing an AI-Based Patient Simulation to Enhance the Integration of Foundational and Clinical Sciences in Didactic Immunology in a US Doctor of Pharmacy Program: A Step-by-Step Prompt Engineering and Coding Toolkit.

Pharmacy (Basel, Switzerland)·2025
Same author

Optimizing pharmacogenomic decision-making by data science.

PLOS digital health·2024
Same author

Abnormal left ventricular subendocardial perfusion and diastolic function in women with obesity and heart failure and preserved ejection fraction.

The international journal of cardiovascular imaging·2023
Same author

QT Prolongation and In-Hospital Ventricular Arrhythmic Complications in Patients With Apical Ballooning Takotsubo Syndrome.

JACC. Clinical electrophysiology·2022
Same author

Contribution of hemoglobin concentration to cardiorespiratory fitness in black African American patients with recently decompensated heart failure and reduced ejection fraction.

Minerva cardiology and angiology·2022

Related Experiment Video

Updated: Jan 23, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.9K

Metabolic modulation predicts heart failure tests performance.

Daniel Contaifer1, Leo F Buckley1, George Wohlford1

  • 1Department of Pharmacotherapy and Outcomes Sciences, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia, United States of America.

Plos One
|June 21, 2019
PubMed
Summary
This summary is machine-generated.

Metabolomic analysis reveals key metabolic changes in heart failure (HF) patients, linking oxidative stress and metabolic syndrome to poor performance in cardiopulmonary exercise testing (CPET) and elevated HF biomarkers.

More Related Videos

Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure
04:20

Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure

Published on: October 1, 2019

6.2K
Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction
08:31

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction

Published on: July 26, 2018

10.9K

Related Experiment Videos

Last Updated: Jan 23, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.9K
Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure
04:20

Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure

Published on: October 1, 2019

6.2K
Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction
08:31

Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction

Published on: July 26, 2018

10.9K

Area of Science:

  • Cardiology
  • Metabolomics
  • Biochemistry

Background:

  • Metabolic alterations in heart failure (HF) patients are not fully understood.
  • Cardiopulmonary testing (CPET) and HF biomarkers (HFbio) are crucial for assessing HF severity.

Purpose of the Study:

  • To investigate the association between metabolomic/lipidomic profiles and CPET/HFbio in HF patients.
  • To identify specific metabolic pathways and biomarkers linked to exercise intolerance and HF progression.

Main Methods:

  • Metabolomic and lipidomic phenotyping of 49 HF patients (LVEF < 50%).
  • Multiple Regression Analysis (MRA) to correlate metabolic data with CPET parameters (Peak VO2, OUES, VE/VCO2 slope) and HFbio (CRP, galectin-3, NT-proBNP).
  • Metabolic Pathway Analysis (MetPA) and Metabolite Set Enrichment Analysis (MSEA) to identify relevant pathways and biological knowledge.

Main Results:

  • Metabolic models for VE/VCO2 slope and Peak VO2 showed the best fit.
  • Acylcarnitine C18:2, palmitic acid, citric acid, asparagine, and 3-hydroxybutiric acid were significant predictors.
  • Associated pathways included amino acid metabolism, fatty acid biosynthesis, and glutathione metabolism.
  • Findings linked to oxidative stress, lactic acidosis, metabolic syndrome, and mitochondrial dysfunction.

Conclusions:

  • Metabolic profiling provides insights into the pathophysiology of exercise intolerance in HF.
  • Identified metabolic signatures correlate with oxidative stress, lactic acidosis, and mitochondrial dysfunction in HF patients.
  • These findings support the metabolic underpinnings of CPET and HFbio in heart failure management.